Recombinant adenoviruses expressing human BRCA1 (AdBRCA1 ), murine Brca1 (AdBrca1 ), three clinically relevant human mutant BRCA1 proteins ( t340, C61G, and 1853Stop ), or a murine Brca1 C -terminal deletion mutant were constructed and evaluated in vitro. These recombinants were capable of transducing high -level transgene expression to a wide variety of cell lines in vitro. Three independent methods were utilized to monitor cell growth following transduction with these recombinants. High -level expression of either the human or mouse wild -type BRCA1 protein was incompatible with maximal levels of cell growth. AdBRCA1 transduction inhibited the outgrowth of several human breast and ovarian cell lines in colony formation assays. Flow cytometric analysis revealed an accumulation of the transduced cells in the G 0 /G 1 phase of the cell cycle. This BRCA1 -mediated accumulation of cells in G 0 /G 1 was accompanied by an increase in the cellular level of hypophosphorylated pRB. Ad mutant BRCA1 t340, C61G, and 1853Stop viruses were impaired, to varying degrees, in their ability to transduce a growth -arrested state to the target cells. Using these same three criteria, overexpression of murine Brca1 by AdBrca1 was also capable of transducing a growth -arrested state to human cells. Deletion of the C -terminus of Brca1 diminished this activity. This panel of adenoviruses may be useful reagents as part of an approach to understand the function of BRCA1 / Brca1 in normal breast and ovary and help to define the tumor suppressor defect ( s ) conferred by clinical BRCA1 mutations in breast and ovarian cell tumorigenesis. Cancer Gene Therapy ( 2001 ) 14,18 In contrast, we have explored the utility of recombinant adenoviruses as a means to provide exogenous BRCA1 to cells. We have previously reported on the use of a recombinant adenoviral vector expressing wild -type human BRCA1 in studies, which suggested a link between the ability of BRCA1 to inhibit cell growth and the RB status of the cell.
T he breast cancer susceptibility gene, BRCA1, and the murine homolog, Brca1, encode multifunctional proteins of 1863 and 1812 amino acids, respectively. Although the precise role of human BRCA1 in breast and ovarian carcinogenesis is not well understood, roles for human BRCA1 or mouse Brca1 have been suggested through studies employing either protein in various in vitro or mouse knockout settings. Roles in embryonic development, 1 ± 3 genome integrity, 4, 5 mammary gland morphogenesis, 6 homologous recombination, 7 ± 9 oxidative DNA damage repair, 10 ± 12 apoptosis, 13, 14 transcriptional ( co-)activation, 15 ± 18 cell cycle regulation, and growth control 19 ± 24 have all been proposed for these proteins. Regulated gene expression has become a powerful tool for the analysis of the protein function 25, 26 and two groups have reported success in generating stable tissue culture cell lines capable of regulated BRCA1 expression. 14, 18 In contrast, we have explored the utility of recombinant adenoviruses as a means to provide exogenous BRCA1 to cells. We have previously reported on the use of a recombinant adenoviral vector expressing wild -type human BRCA1 in studies, which suggested a link between the ability of BRCA1 to inhibit cell growth and the RB status of the cell. 19 Herein, we further describe and expand on our initial findings with first generation, E1 /E3 -deleted, recombinant adenoviruses, which express either human BRCA1, any of three clinically validated BRCA1 mutants, murine Brca1, or a C -terminal Brca1 deletion mutant. These recombinants were capable of transducing readily detectable levels of wild -type or mutant BRCA1 /Brca1 transgenes to a wide variety of cell lines. High -level expression of wild -type BRCA1 was found to be growth inhibitory to human tissue culture cells, whereas all three BRCA1 mutants were impaired, relative to wild -type BRCA1, in their ability to retard cell growth. Overexpression of murine Brca1 was also growth inhibitory to human cell lines. Deletion of the C-terminus of murine Brca1 decreased its growth inhibitory activity. Moreover, the level of cellular hypophosphorylated pRB correlated with the degree of growth inhibition conferred by these vectors. These results are consistent with our previous observation that the BRCA1-associated growth arrest is dependent, in part, on the pRB pathway.
MATERIALS AND METHODS

Cell lines
The HCC 1937 27 breast carcinoma cell line was obtained from Gail Tomlinson (Hamon Cancer Center, Dallas, TX ). MCF -7, SKBR -3 ( human breast carcinoma ), ES -2, PA -1 ( human ovarian carcinoma ), and U2OS (human osteosarcoma ) were obtained from the ATCC ( Manassas, VA ) and human mammary epithelial cells ( HMEC ) were obtained from Clonetics ( Walkersville, MD ). Mouse embryo fibroblasts (MEFs ) were obtained from the Vanderbilt Transgenic Core Facility. All cells were cultured as recommended by the suppliers.
Adenovirus construction and transduction
The BRCA1 cDNA used in the construction of these adenoviruses was fully sequenced before use in these studies and resequenced in the context of the final recombinant adenoviral plasmid. The murine Brca1 cDNA was a gift from Allan Bradley (Baylor University School of Medicine ) and was also completely sequenced before use. Mutants were constructed by PCR mutagenesis or restriction enzyme digestion. Introduced mutations were sequence -verified. BRCA1 mutant C61G is a missense mutation located in site II of the BRCA1 C3HC4 ( RING -HC ) N -terminal RING finger domain. The 1853Stop ( Y1853insA ) mutation is located at the extreme Cterminus of the second BRCT repeat and truncates BRCA1 11 amino acids before the authentic stop codon. Mutant BRCA1 t340 contains a stop codon at amino acid 340 (del 1010A ), resulting in a protein truncation of 116 amino acids into exon 11. The Brca1ÁHindIII ( AdBrca1ÁH3 ) deletion results in a predicted 142-kDa protein product, consisting of the first 1295 Brca1 amino acids, two out -of -frame amino acids, followed by a termination codon. Further details of these constructions are available upon request. Recombinant adenoviruses were constructed using the procedure of He et al. 28 Briefly, linearized adenoviral CMV shuttle vector DNA containing the cDNA insert of Cancer Gene Therapy, Vol 8, No 3, 2001 interest and the supercoiled adenoviral backbone plasmid ( Ad Easy -1 ) were co -electroporated into Escherichia coli strain BJ5183 and the products of homologous recombination were analyzed after selection for kanamycin resistance. Positive clones were verified by restriction and sequence analysis. Viral stocks were produced, banded, titered, and transduced as described. 28 Cells were transduced at the multiplicity of infection (MOI) listed in the figure legends. Three control recombinant adenoviruses, Adnull (no transgene insert), AdG ( expressing -galactosidase ), or AdGFP ( expressing green fluorescent protein from pEGFP; Clontech, Palo Alto, CA ), were utilized as controls in these studies.
Analysis of transgene expression
Transduced cells were harvested for Western blotting at 24 hours postinfection (p.i. ). One -hundred -microgram aliquots (50 g for t340 expression ) of total protein were electrophoresed on 7% sodium dodecyl sulfate polyacrylamide gel electrophoresis ( SDS -PAGE ) gels, blotted to PVDF membranes (Immobilon -P, Millipore, Bedford, MA ), and probed overnight at 48C with the various primary antibodies as listed in the figure legends. Appropriate secondary antibodies were added and detection was accomplished by enhanced chemiluminescence. Dilutions used for all antibodies were as recommended by the supplier. For Northern analysis, total RNA was prepared at the indicated times p.i. using the RNeasy protocol ( Qiagen, Valencia, CA ). Twenty micrograms of total RNA was electrophoresed under denaturing conditions on 1% agarose, blotted to nylon membranes ( Hybond N; Amersham Pharmacia Biotech, Piscataway, NJ ), and hybridized with [ 32 P ]-labeled random -primed DNA probes. Human BRCA1 transcripts were detected with a 5.7 -kb NotI± HindIII DNA fragment encompassing the full -length human BRCA1 cDNA. Murine Brca1 transcripts were detected with a 1.9 -kb HindIII ( nt 3778 ± 5736 ) ( Fig 1A ) or a 3.8-kb SalI±HindIII ( Fig 3E ) mouse Brca1 fragment ( nt 1 ±3778 ). Hybridizations were carried out in Quik -Hyb ( Stratagene, La Jolla, CA ). Following washing, the blots were exposed to X -ray film at À 708C. The GAPDH probe was obtained from Ambion (Austin, TX ), labeled, and used as described above.
Colony formation assay
Cells were seeded at a density of 2000 (MCF-7, ES -2, PA -1, U2OS ) or 4000 ( HCC 1937 ) cells per well in six -well tissue culture plates 2 days before transduction. Following transduction, the cells were cultured for 10 ± 14 days; the duration of the culture H and 3 H untranslated regions; thus, the mRNAs produced via the recombinants is smaller than the endogenous major BRCA1 transcript ( %7.8 kb, * in HCC1937 lanes, not visible in U2OS lanes ) or endogenous mouse Brca1 transcript ( %7.2 kb, not shown ). The position of the 28S rRNA is shown. The AdBrca1 blot was stripped and re -probed with a GAPDH probe as a representative loading control. The position of the 18S rRNA is shown. B: Western blot analysis of the BRCA1 produced via AdBRCA1. HCC 1937 cells were transduced with AdG ( lanes 1, 3, 5, 7, 9 ) or AdBRCA1 ( lanes 2, 4, 6, 8, 10 ) ( MOI 5Â10
3 ). Twenty -four hours p.i., lysates were prepared for Western analysis as described in the Materials and Methods. The blot was cut into strips and reacted with the antibodies listed above the lanes. MS -110 and MS -13 ( Calbiochem, San Diego, CA ) are mouse monoclonal antibodies directed against the N -terminus of BRCA1. Ab -C ( PharMingen, San Diego, CA ) is a rabbit polyclonal antibody directed against a BRCA1 exon 11 epitope, and C -20 ( Santa Cruz ) and Ab -D ( PharMingen ) are rabbit polyclonal antibodies directed against a C -terminal BRCA1 epitope. The arrow indicates the %220 -kDa BRCA1 produced. The MW marker is listed. CAMPBELL, APRELIKOVA, VAN DER MEER, ET AL: RECOMBINANT BRCA1/Brca1 ADENOVIRUSES period was a function of the growth rate of the mock -transduced cells. At the indicated day p.i., the cells were fixed and stained with 0.2% crystal violet for 20 minutes. Excess stain was removed by washing and the plates were air-dried and colonies were scored.
Flow cytometry
Duplicate cultures of cells were plated at 6Â10 5 cells/ 100 mm dish 24 hours prior to transduction. Cells were transduced with the recombinant adenoviruses as described in the legend for Figure 4 . Cell cycle distribution was analyzed using FACscan ( Becton Dickinson ) 48 hours p.i. One set of plates was treated with nocodazole for 12 hours prior to fixation as previously described. 19 
RB phosphorylation status
Cells were plated at 2Â10 5 cells/100 mm dish 24 hours before transduction. Cells were transduced with the recombinant adenoviruses as described in the legend . The transduced cells were cultured for 10 ± 14 days as shown in the figure. At the indicated day, the colonies were stained with 0.2% crystal violet. The assay duration variation reflects the differing growth rates among each mock -transduced control. One of three independent experiments is shown. B: Quantitation of colony outgrowth. Colony outgrowth was scored and plotted as a percentage of the number of colonies in the mock -transduced well. Values represent the mean of three independent experiments utilizing different adenovirus preparations. Where error bars are not seen, the SE was too small to be visualized on the graph. Abscissa labeling for all graphs is as shown for ES -2 / day 10.
Cancer Gene Therapy, Vol 8, No 3, 2001 for Figure 1F . Seventy -hours p.i., the transduced cells were harvested for Western blotting. Fifty-microgram aliquots of total protein were electrophoresed on 8% SDS -PAGE gels and processed for pRB Western blotting as described above for BRCA1 blotting. The primary antibody was C -15 (Santa Cruz ). Blotting for BRCA1 was done in parallel as described above for the analysis of transgene expression.
RESULTS
Adenoviral-mediated transgene expression
Recombinant adenoviruses expressing wild -type human BRCA1, one of three clinically validated human BRCA1 mutants, wild -type mouse Brca1, or a C -terminal Brca1 deletion mutant were constructed and evaluated for their ability to transduce exogenous BRCA1 /Brca1 expression in vitro to a variety of tissue culture cell lines. Relatively high MOIs ( !500 ± 1000 ) were needed to clearly document expression by Western blotting (Fig 1B and E ) , although exogenous transgene expression could be detected by Northern blot at lower MOIs (Fig 1A ) . The minimal MOI needed to unambiguously detect expression was cell type ± dependent (Fig 1A, data not shown ) . Using a high MOI, transduction of a wide variety of breast and ovarian cell lines resulted in high levels of readily detectable transgene expression ( Fig 1A ±C ) . High-level expression was also observed following transduction of primary HMEC, MEF, and mouse embryonic stem (ES ) cells (Fig 1C, data not  shown) . The human BRCA1 produced via these adenoviruses was reactive with a variety of BRCA1 antibodies directed against the N -terminus, middle portion (exon 11 ), and C -terminus of BRCA1 ( Fig 1B ) . At a given MOI, 3 ). Eight hours p.i, total RNA was harvested from the transduced cells and a 20 -g aliquot was analyzed by Northern blotting. The blot was probed with a 3.8 -kb SalI ± HindIII mouse Brca1 fragment ( nt 1 ± 3778 ). The arrows indicate the full -length $5.5 -kb Brca1 ( Brca1 ) or the $4 -kb Brca1 HindIII deletion ( ÁH3 ) transcripts produced. The position of the 28S rRNA is shown. The blot was stripped and re -probed with a GAPDH probe as a loading control.
Cancer Gene Therapy, Vol 8, No 3, 2001 CAMPBELL, APRELIKOVA, VAN DER MEER, ET AL: RECOMBINANT BRCA1/Brca1 ADENOVIRUSES BRCA1 mutant C61G and 1853Stop proteins were produced at levels comparable to those of the wild -type protein ( Fig  1E ) . BRCA1 mutant t340 protein was expressed at greater levels than any of the full -length proteins, perhaps due to its smaller size ( Fig 1D and F ) . Exogenous mouse Brca1 and Brca1ÁH3 expression was readily detected by Northern blotting (Figs 1A and 3E ). Attempts to demonstrate murine Brca1 protein using two commercially available antibodies directed against murine Brca1 (Santa Cruz) were unsuccessful. However, murine Brca1 protein expression was confirmed by constructing a recombinant adenovirus directing expression of wild -type Brca1 with an N -terminal Myc epitope tag and probing Westerns with anti -Myc antibody ( data not shown ).
Effect of transgene expression on cell growth
Transduced cells were evaluated for their growth potential by three independent methods: colony formation assays ( Figs 2  and 3) , cell cycle / flow cytometric analysis (Fig 4) , and pRB phosphorylation status (Fig 1F ) . Transduction with AdBRCA1 (Figs 2 and 3) or AdBrca1 ( Fig 3 ) resulted in decreased colony outgrowth relative to mock, Adnull, or AdGFP controls. In addition, the growth inhibitory potentials of AdBRCA1 mutants C61G, 1853Stop (Fig 2A ) , and t340 ( data not shown) were all impaired relative to wildtype BRCA1. Quantitation of the emergent colonies ( Fig  2B ) suggests that the C61G mutant is impaired $3 -fold, whereas the 1853Stop mutant is impaired $ 2± 3-fold in the ability to inhibit colony outgrowth relative to wild -type BRCA1. The growth inhibitory activity of the t340 mutant is the weakest among the BRCA1 recombinants that we have evaluated ( $4 ± 5-fold relative to wild -type BRCA1, data not shown). AdBrca1 was also able to inhibit colony outgrowth of human cells in this assay as effectively as AdBRCA1 (Fig 3A ± C ) . Deletion of the $C -terminal 500 amino acids of Brca1 diminished its growth inhibitory activity in this assay by $2 ± 3-fold ( AdBrca1ÁH3; Figure  3C and D ). We repeated this type of experiment with three different preparations of each adenovirus and obtained 
d w i t h t h e r e c o m b i n a n t adenoviruses ( MOI 2Â10
3 ) as given on the left side of the figure. Cell cycle distribution was analyzed using FACscan ( Becton Dickinson ) 48 hours p.i. One set of plates was treated with nocodazole for 12 hours ( + NOC ) prior to fixation as previously described. 19 A minimum of 10,000 events was scored. The cell cycle distribution of each sample is given as a percent of the total cell population in the upper right of each histogram.
Cancer Gene Therapy, Vol 8, No 3, 2001 similar results, suggesting that the observed relative growth inhibition is a genuine property of the expressed transgene. Based on these observations, the hierarchy of these recombinant's ability to inhibit colony outgrowth of the human cells we have evaluated is BRCA1/ Brca1 > 1853S-top > C61G >t340 / ÁH3.
We also examined the cell cycle profile of one breast and one ovarian cell line which showed reduced colony outgrowth following AdBRCA1/ AdBrca1 transduction ( Fig 4 ) . Flow cytometric analysis of cell populations 48 hours p.i. revealed an accumulation of AdBRCA1/ AdBrca1 transduced cells in the G 0 /G 1 phase of the cell cycle. This effect was observed in these transduced cells with (Fig 4; + NOC ) or without ( Fig 4; À NOC ) nocodazole treatment; however, the effect was sometimes more evident in cultures treated with the mitotic inhibitor nocodazole, which unmasks cells arrested in G 1 (Fig. 4 of Ref. 19 ). Consistent with the colony formation assay results, we observed that the AdBRCA1 C61G and AdBRCA1 1853Stop mutants were less able to confer a G 0 /G 1 arrested state to the transduced cells at early time points p.i., with the 1853Stop mutant again retaining function closer to the wild -type protein than the C61G (Fig 4) or t340 ( data not shown) mutants.
The accumulation of transduced cells in G 0 /G 1 (Fig 4) prompted us to look at the status of RB phosphorylation as another indicator of cellular proliferative potential in the context of BRCA1 overexpression. An example of this type of analysis is shown in Figure 1F . We had previously observed a G 0 /G 1 arrest in AdBRCA1-transduced U2OS cells. 19 Consistent with this observation, more hypophosphorylated RB is detected in AdBRCA1 and AdBrca1 transduced cells relative to mock or Adnull -transduced controls (Fig 1F, upper panel ) . In contrast, the accumulation of hypophosphorylated RB species is reduced in cells transduced with the BRCA1 mutants ( Fig 1F) in a manner consistent with the results from both the colony formation assays (Figs 2 and 3 ) and flow cytometry ( Fig 4 ) . High levels of ectopic BRCA1 /mutant BRCA1 proteins were detected in these transduced cells (Fig 1F, lower panel ) . Moreover, large amounts of BRCA1 mutant t340 protein are present in Adt340 transduced cells, yet the various forms of phosphorylated RB observed in the mock and AdNulltransduced cells are still detected by Western blotting in these transductants, suggesting that high -level expression of exogenous protein, per se, is not the explanation for the appearance of hypophosphorylated pRB ( Fig 1F ) and cell cycle perturbations observed by flow cytometry ( Fig 4 ) ( i.e., cellular protein overload). Similar results were obtained when this type of analysis was performed using MCF -7 and HCC 1937 cells (data not shown).
DISCUSSION
We have constructed first -generation, E1 / E3-deleted, recombinant adenoviruses as a method for the introduction of exogenous human BRCA1 or mouse Brca1 protein into cells. We have demonstrated in this report that these adenoviruses can transduce high -level expression of wildtype BRCA1 or Brca1 (Fig 1 ) . The level of BRCA1 expression can be modulated by manipulation of the MOI, with the MOI needed for a given level of expression dependent on the cell line in question ( Figs 1A and C ) . The ability of these viruses to transduce a variety of cell lines including primary HMEC and MEF adds to their usefulness and potential to address varied scientific questions ( i.e., restoration of putative Brca1 function to Brca1 knockout MEFs, microarray studies, etc. ) (Fig 1C) . High-level expression of BRCA1 or Brca1 was incompatible with maximum levels of cell growth (Figs 2 ±4 ) as has been reported previously using plasmid or retroviralmediated expression of BRCA1. 12 ± 14,19 ± 21,23 In certain cell lines, this inhibition is accompanied by a G 0 /G 1 arrest; however, this effect is cell type ± dependent. 19, 20, 23, 29 We also observed in two cell lines an accumulation of cells in G 0 /G 1 at early time points p.i. following transduction with AdBRCA1 /AdBrca1. We have utilized three independent methods to demonstrate that, when overexpressed, the growth inhibitory activity of three BRCA1 mutants is impaired to various degrees relative to wild -type BRCA1.
The extent of accumulation of cells in G 0 /G 1 ( Fig 4 ) and the pRB phosphorylation status (Fig 1F ) correlated with the results of the colony formation assays ( Figs 2 and 3 ) , suggesting that the observed pRB hypophosphorylation and G 0 /G 1 delay may contribute mechanistically to the decreased outgrowth detected in colony formation assays. We have not observed a rapid onset of apoptosis in AdBRCA1 transduced cells (including U2OS or MCF -7 ) as has been reported, 14 although at later time points ( > 72 ±96 hours p.i. ) we have observed dead and dying cells in the colony formation assays, suggesting that prolonged overexpression of BRCA1 or Brca1 is incompatible with cell viability. Although the contribution of BRCA1 -associated growth arrest to its role as a tumor suppressor is still controversial, this correlation is supported herein by the fact that three clinically relevant BRCA1 mutants were all impaired in their ability to inhibit cell growth relative to wild -type BRCA1, when overexpressed, albeit to various degrees and in a cell line ± dependent manner. Although the emerging role of BRCA1 is that of a caretaker, 1 ± 12 the large size of this protein may be indicative of multiple functions, including roles more akin to gatekeepers. 17,19 ± 24,29 A degree of growth inhibition specific to transgene expression is evident in all examples provided in Figs 2 and 3; however, substantial nonspecific viral toxicity was observed in certain cell types while attempting to document an effect by AdBRCA1 on colony outgrowth (data not shown ). We hypothesized that part of this effect is do to viral ±host events occurring at the cell surface. Accordingly, we have re -configured these adenoviral vectors with a modified Ad fiber containing the RGD -4C peptide in the HI loop of the Ad fiber knob 30 ( M. C., Shimian Qu, and R. A. J., unpublished results ). Our preliminary observations suggest that, in certain cell types, this modification results in detectable levels of transgene expression in vitro at a 10± 100-fold lower MOI than that needed for unmodified Ad5 ( Ad Easy -1 ) -based vectors. This modification may obviate some of the nonspecific viral effects we have observed.
Cancer Gene Therapy, Vol 8, No 3, 2001 CAMPBELL, APRELIKOVA, VAN DER MEER, ET AL: RECOMBINANT BRCA1/Brca1 ADENOVIRUSES Another group has reported on the construction and utility of adenoviruses expressing BRCA1. 29 Our results are consistent with theirs 29 in regard to perturbation of the cell cycle and lack of rapid onset apoptosis 14 by AdBRCA1. However, our panel of clinically relevant BRCA1 mutants adds to the potential of these vectors to address issues as to the nature of the defect (s) mapping to specific regions of the BRCA1 such as the RING finger (AdC61G ) or BRCT repeats (Ad1853Stop ). In addition, although there are regions of complete identity such as the RING finger and extreme Cterminus, murine Brca1 and human BRCA1 proteins exhibit only 58% identity (73% similarity ). This represents considerably less overall homology than that observed when comparing other tumor suppressors between these two species. 31 Thus, AdBrca1 serves as a necessary control between human BRCA1 and mouse Brca1 in comparative studies employing mouse knockout ES cells or MEFs. 5 ± 8,11 In this study, we focused on growth inhibition and cell cycle effects as functional assays for BRCA1. In addition, we are evaluating these vectors in a model system of homologous recombination, 7 transcription -coupled repair, 11, 12 and in ubiquitination 32 in an attempt to define more precisely the role of Brca1 /BRCA1 in these processes. We anticipate that our ability to direct the expression of wild -type BRCA1 and selected mutants in relevant model systems will greatly enhance our efforts to perform a comprehensive structure / function analysis of BRCA1 /Brca1. This in turn should result in a more complete understanding of the role of BRCA1 in normal physiology, development, and tumorigenesis.
